How to Teach This Book

Understanding Peptides looks like a survey course about a class of molecules. It is not, and teaching it as one will produce students who can tell you what BPC-157 is and cannot tell you whether the next compound they encounter is worth their attention. The molecules are the material. The method is the course.

This guide is written for whoever is standing in front of the room — a general-education instructor, a first-year seminar leader, a pharmacology preceptor, a continuing-education facilitator with eight sessions and a room full of nurses. What follows is what the book is doing under the surface, where students reliably fall off, and how to run the term so they land somewhere useful.

1. What the book is actually teaching

The thesis is stated in Chapter 1 and never abandoned: "it's a peptide" tells you almost nothing. Insulin and BPC-157 are both peptides. The distance between them is not chemical — it is evidentiary, and it is roughly the distance between a century of clinical practice and a promising rat study.

Everything downstream follows from taking that seriously. If "peptide" is not a meaningful category for deciding anything, then the student needs a different tool, and the book gives them exactly one: a disciplined procedure for turning a vague claim into a specific one, finding out what has actually been measured, and attaching a rating to it that carries a date and a condition for revision.

That procedure is transferable and the peptide content is not. A student who leaves your course able to evaluate a supplement claim, a nutrition headline, or a device marketing page has gotten the thing. A student who leaves able to recite forty peptide verdicts has memorized a snapshot that will be partly wrong within two years.

Say this to your students in week one, and mean it. They will not believe you until the first assessment confirms it, so make sure the first assessment confirms it.

2. The central pedagogical claim: the rating system is the course

The book applies a four-tier rating throughout: ✅ strong clinical evidence · ⚠️ promising but preliminary · ❌ hype outpaces evidence · 🔬 frontier. Six rules govern it, and they are frozen — the book states them in Chapter 5 and never bends them:

Teach these as rules of a game with a fixed rulebook, not as guidelines. Students negotiate with guidelines. The rules are also, conveniently, a grading instrument — nearly every error worth marking on a dossier entry or an exam answer is a violation of one of the six, and naming the number in your feedback is faster and clearer than a paragraph of prose. "Rule 3" on a margin does more work than "you've leaned too hard on the mechanism here."

The evaluative standard follows from the rules, and it is worth announcing early:

A well-reasoned ⚠️ that the instructor disagrees with outscores a ✅ that happens to match the book. Reasoning is the graded object. Agreement is not.

Students find this disorienting for about three weeks and then it becomes the most liberating thing about the course. It is also the only defensible position, because the book's own ratings are date-stamped and some of them will be wrong by the time you teach it.

3. How the parts build

The eight parts are not eight topics of equal weight. They are a method, four demonstrations of the method at increasing difficulty, two contextual layers, and an assembly.

Part I (1–6) — The Science of Peptides. The toolkit. Chapters 1–4 give students just enough biochemistry and pharmacology to reason about the rest; Chapters 5 and 6 give them the method itself. See §4 — these two are load-bearing.

Part II (7–13) — Metabolic Peptides. The method applied where the evidence is strongest. This ordering is deliberate and you should preserve it. Students meet the rating system first in a domain where large trials with hard outcomes exist, so they learn what a ✅ actually looks like before they ever have to identify its absence. Chapter 8 (semaglutide) is the book's reference implementation of a full evaluation.

Part III (14–19) — Growth and Repair. The same method where the evidence is thinnest, and the contrast is the lesson. Chapter 17 (BPC-157) is the mirror of Chapter 8 — same twelve fields, same procedure, radically different result. Chapter 19 (the gray market) introduces the risk layer that has nothing to do with whether a molecule works.

Part IV (20–24) — Neuropeptides and Social Peptides. Where mechanism is most seductive and outcome data most disappointing. Chapter 22's failed antagonists are the book's cleanest demonstration of Rule 3: the target was engaged exactly as designed, and the drug did not work.

Part V (25–31) — Peptides in Medicine. Breadth. The point of this part is that most peptide medicine is unglamorous, decades old, and already in the pharmacy. It is the antidote to the idea that peptides are an emerging frontier phenomenon.

Part VI (32–36) — Science and Technology. Manufacture, engineering, analysis, discovery, future. Chapters 32 and 34 are what make the Chapter 19 quality argument concrete rather than hand-waving.

Part VII (37–40) — Synthesis and Reference. The master table, regulation, the clinical conversation, and the capstone. Chapter 40 is assembly, not new content.

Part VIII (41–44) — Peptides in Public Life. Language, creators, enhancement, society. This part is frequently cut for time and it is the wrong thing to cut in a general-education setting, because it is where most students' actual exposure to the subject lives.

4. Chapters 5 and 6 are load-bearing

Do not skip them. Do not compress them into one session. Do not assign them as background reading before the "real" content starts.

Chapter 5 (Evaluating Peptide Evidence) is the method: population, endpoint, comparator, design, size, duration, replication, and what is conspicuously absent. Every later chapter assumes it. A student who has skimmed Chapter 5 will spend the rest of the term producing confident paragraphs about mechanism, because mechanism is the easiest thing to write and requires none of Chapter 5's apparatus.

Chapter 6 (The Peptide Hype Cycle) is the immune system. It also contains the instruction to write field 12 — what would change my mind — before you are invested, which is the single most important sequencing decision in the book. Field 12 written in week three is honest. Field 12 written in week fourteen, after a student has spent a term defending a compound in seminar, is a formality.

Practical guidance:

• Budget two full sessions for Chapter 5, one on the vocabulary and one on application. Students need to use population/endpoint/comparator on something before it becomes real.
• Assign Appendix D (Reading a Clinical Trial) alongside Chapter 5, not later. It is the procedural companion.
• Use Appendix H (Twenty Worked Evidence Evaluations) as a graduated problem set, not as reading. Work two together, assign two, and keep the rest in reserve for the students who need more reps.
• Return to Chapter 6 late in the term. Rating drift (see the common-struggles guide, struggle 10) is best diagnosed by having students re-read their own week-three field 12 in week thirteen.

If your calendar forces a cut, cut a content chapter. Cutting Chapter 5 does not save time; it relocates the time to your office hours.

5. Running the dossier project across a term

The Peptide Evidence Dossier is the deliverable. Students choose five to ten peptides in the first two weeks and build a twelve-field entry for each, incrementally, across the term. Appendix C is the blank workbook and the field-by-field guide; Chapter 40 is the assembly.

The design principle that makes it work: fields are filled as the book teaches them, one or two at a time, never all at once. A dossier written in a single sitting at the end of term is twelve paragraphs of mechanism and no verdicts. You can spot one instantly and you should grade it as what it is.

A workable term rhythm:

Three enforcement mechanisms that matter more than they sound:

1. Collect the compound list early and hold students to it. Students who swap compounds in week ten are usually escaping a compound with no evidence, which is exactly the entry they should keep. A dossier of five well-evidenced compounds teaches half the lesson.
2. Require sources in the margin from day one. Appendix C's instruction — if you write nothing else in the margin, write where you got it — is the difference between a maintainable file and a pile of plausible sentences.
3. Grade blanks favorably. An honest empty field is worth more than a filled one the student cannot source, and students will not believe this until they see it in a returned grade.

Chapter 40 is an assembly session, not a writing session. If students are still drafting entries in week fourteen, the incremental structure failed somewhere upstream and the fix is earlier checkpoints, not a longer deadline.

6. The callout taxonomy

Eight recurring callouts run through the chapters. Students learn to read them as functional signals rather than decoration, and you can lean on that:

The 📊 reveal exercise is the single best routine in the course. Project the claim, hide the rating, have students commit to one of the four tiers with one sentence of justification, then show the book's rating and — more importantly — discuss the cases where the class was split. Split cases are almost always cases where students disagreed about the claim, not about the evidence, which is Rule 1 teaching itself.

7. The three citation-honesty tiers

The book is unusually explicit about how confident its own sourcing is, and it uses three tiers consistently:

1. Named and checkable. A specific trial, drug, or agency action is named so the reader can go look it up. Used where the book is confident and the reader should verify.
2. Described but unnamed. A body of work is characterized by design and result — a large randomized trial in this population found… — without a name attached, because attaching one would imply a precision the text is not claiming. Used where the shape of the literature is the point.
3. Explicitly constructed. A [constructed teaching example] — an invented claim, marketing page, or abstract built to exercise the method. Always marked, never citable, never presented as real.

Teach the tiers out loud. Two reasons. First, students who do not know tier 2 exists will treat every unnamed description as either a citation or a fabrication, and neither reading is right. Second — and this is the reason worth the class time — the tiers are a model of the behavior you want in their own work. A student who learns to write "a randomized trial in this population found X, and I have not read it directly" instead of inventing a plausible reference has learned something that will outlast the course.

Enforce tier 3 in student work: anything invented for illustration must be labeled as invented. An unlabeled constructed example in a dossier is not a small formatting error; it is the exact failure the book spends forty-four chapters teaching against, and it should be graded that way.

8. The classroom-management section that matters most

Some of your students are currently taking these compounds. Not hypothetically. In a general-education room of thirty, in a fitness-adjacent elective, in a continuing-education session for trainers — assume it, plan for it, and never ask.

This is the part of teaching this book that goes wrong, and it goes wrong in ways that are hard to repair once they happen.

Never require disclosure. Not as an icebreaker, not as a survey, not as an anonymous poll that a class of twelve can deanonymize, not as a "raise your hand if you know someone." A student's medical history is not course material. There is no pedagogical benefit that justifies it, and there is real harm available: a student who is on a GLP-1 for a diagnosed condition, a student who is using a gray-market compound and is now frightened, a student who is neither and is about to be assumed to be one of the two.

Never make a student the case study. If a student volunteers their own use — some will, and often generously — thank them, and then move to the claim rather than the person. "That's a useful example of the claim we're evaluating" is a bridge. "Let's look at your case" is a trap that ends with a room of thirty people discussing one person's body.

Keep the discussion about claims rather than choices. This is the operational rule and it resolves almost every difficult moment. Does the evidence support this claim for this population? is a question a class can answer together. Should this person be taking this? is not, and the class will answer it anyway if you let the framing slip. The rating system is genuinely useful here: it is constructed to rate claims, and Rule 2 — ❌ describes the evidence, not the molecule — extends naturally to and certainly not the person taking it. Say that extension out loud in the first week.

Be aware that a dismissive tone teaches concealment. This is the failure with the longest tail. An instructor who signals contempt for gray-market compounds — the eye-roll at BPC-157, the joke about biohackers — does not change what students take. They change whether students will ever ask a question about it, in your classroom or in a clinic. Chapter 39 (Talking to Your Doctor) is entirely about this dynamic on the clinical side; the classroom version is identical and instructors are less aware of it. A student who conceals is a student in more danger, not less, and the concealment generalizes to the physician they will not tell either.

The tone to aim for is the book's own: serious about the evidence, unbothered by the person. A compound can be rated ❌ with real conviction in a room where someone is taking it, provided the ❌ is clearly about the state of the literature and provided nobody is asked to account for themselves.

Practical mechanics that help:

• Use constructed examples for anything sensitive. That is what tier 3 is for.
• Let dossier compounds be chosen privately. Students may share; do not require it.
• Offer a no-questions alternative if a student's chosen compound would expose something personal.
• Have a referral answer ready. When a student asks a direct personal question — and one will — the answer is Chapter 39's answer: this is a question for a clinician who knows your history, and here is how to raise it so it gets answered rather than dismissed. That is a real answer, not a deflection, and students can tell the difference.

9. The book's own guardrail — hold student work to it

The book contains no dosing, no protocols, no sourcing, and no vendors. Anywhere. Deliberately.

This is not squeamishness and it is not a legal hedge. It is a pedagogical position: the book's claim is that the interesting question is what does the evidence support, and a protocol answers a different question — how would I do this — that presumes the first one has been settled. Every dosing table is an implicit ✅.

You will notice the absence in places where it feels awkward, including in the exams in this guide, which discuss compounds at length without a single milligram figure that is not part of a labeled constructed example. That awkwardness is the design working.

Hold student work to the same rule, and state it in the syllabus. Dossiers, presentations, and discussion posts should contain no dosing, no protocols, no sourcing information, no vendor names, and no links to sellers. Students will not expect this rule and a few will trip it innocently — a "typical protocol" line copied from a forum into field 4, a supplier screenshot pasted as evidence of field 10. Treat the first instance as a teaching moment and the second as a graded one. Field 4 asks about route and half-life, not about regimens, and the distinction is worth ten minutes of class time before the first submission.

One useful framing for students who push back: the book can tell you that a compound has been studied by subcutaneous injection at a weekly interval, because that is a fact about the evidence. It will not tell you what to inject, because that is a fact about your body that a book cannot know.

10. What to grade

Three instruments, all in this guide, all pointing the same direction:

• The dossier rubric rewards claim specificity, evidence described by design rather than by count, dated ratings, an honest and specific field 12, blanks where nothing is known, and consistency across entries.
• The claim-evaluation rubric handles shorter assignments — one claim found in the wild, worked properly.
• The participation rubric grades a behavior most rubrics ignore: changing one's mind in response to evidence. Make this explicit early. Students arrive believing that changing position in a seminar is a loss, and the belief is load-bearing for a lot of bad discussion.

Across all three, the same standard: reasoning is the graded object. Verdicts are not.

11. If you teach only one thing

Teach Rule 1 until it is a reflex. A rating attaches to a claim, with a population and an endpoint, never to a molecule. Everything else in the book is downstream of it, every common student error is a variation on violating it, and it is the only part of the course that will still be doing work for your students in ten years, when every rating in Appendix A has been revised and most of the compounds have been replaced by compounds nobody has named yet.

Related: Chapter 5 (the method) · Chapter 6 (hype cycle; field 12 early) · Chapter 39 (the clinical conversation) · Chapter 40 (capstone assembly) · Appendix C (dossier workbook) · Appendix D (reading a trial) · Appendix H (worked evaluations) · Appendix M (answers) · Where Students Get Stuck · the three syllabi · the three rubrics